BioMarin Pharma Q2 Loss Widens; 2015 Guidance Unchanged - Quick Facts

(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) reported a second quarter net loss of $82.0 million, or $0.51 per share compared to a loss of $33.5 million, or $0.23 per share for the second quarter of 2014. Non-GAAP net loss was $5.4 million for the second quarter of 2015. The company said the increased net loss was primarily due to increased operating expenses, partially offset by increased revenues due to the strong commercial launch of Vimizim.

On average, 16 analysts polled by Thomson Reuters expected the company to report a loss per share of $0.53 for the quarter. Analysts' estimates typically exclude special items.

Total BioMarin Revenue was $250.5 million, an increase of 31% compared to the second quarter of 2014. The company said this increase was driven by solid growth across all BioMarin products including Kuvan, Naglazyme and Vimizim. On a constant currency basis, total BioMarin revenue in the second quarter would have been approximately $260.5 million. Analysts expected revenue of $218.16 million for the quarter.